Effects of Camrelizumab Combined with TP Regimen on Efficacy Immune Function and Peripheral Blood VEGF bFGF CA125 and CEA in Patients with Intermediate to Advanced NSCLC
YU Dongshan, XIA Xiaoyang, CHEN Aimin, et al
Chuzhou Hospital Affiliated to Anhui Medical University / Chuzhou First People's Hospital, Anhui Chuzhou 239000, China
Abstract：Objective: To observe the effects of camrelizumab combined with TP chemotherapy regimen (paclitaxel + cisplatin) on efficacy, immune function, peripheral blood vascular endothelial growth factor (VEGF), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and basic fibroblast growth factor (bFGF) in patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 102 patients with advanced NSCLC admitted to our hospital from January 2020 to January 2023 were selected and divided into two groups by simple random method. The control group was treated with TP regimen, and the observation group was additionally treated with camrelizumab. The effects, immune function, and peripheral blood factors of the two groups were compared, and the toxic and side effects of the two groups were counted. Results: The objective remission rate (ORR) and disease control rate (DCR) in the observation group were 56.86% (29/51) and 80.39% (41/51), which were higher than those in the control group (33.33% (17/51) and 58.82% (30/51), and the difference was statistically significant (P<0.05). Before treatment, there was no significant difference in VEGF, bFGF, CA125, CEA and immune function between the two groups (P>0.05). Compared with before treatment, VEGF, bFGF, CA125, CEA, and CD8+ decreased after treatment, while CD4+ and CD4+/CD8+ increased after treatment. The difference before and after treatment in the observation group was greater than that in the control group (P<0.05). There was no significant difference in the incidence of stomatitis, peripheral nerve abnormality, alopecia, bone marrow suppression, gastrointestinal reaction, abnormal liver or kidney function, reactive cutaneous capillary hyperplasia grade Ⅲ to grade Ⅳ between 2 groups (P>0.05). Conclusion: Camrelizumab combined with TP regimen in the treatment of advanced NSCLC can effectively improve ORR and DCR, improve immune function, inhibit the expression of VEGF, bFGF, CA125 and CEA in peripheral blood, while not increasing toxic and side effects.
尤冬山, 夏晓阳, 陈爱民, 黄景慧, 曹静. 卡瑞利珠单抗联合TP方案对中晚期NSCLC患者疗效免疫功能及外周血VEGF bFGF CA125和CEA的影响[J]. 河北医学, 2023, 29(10): 1743-1748.
YU Dongshan, XIA Xiaoyang, CHEN Aimin, et al. Effects of Camrelizumab Combined with TP Regimen on Efficacy Immune Function and Peripheral Blood VEGF bFGF CA125 and CEA in Patients with Intermediate to Advanced NSCLC. HeBei Med, 2023, 29(10): 1743-1748.
2023, Vol. 29 
冀公网安备13080202000677号